drugset / Trial / NCT05600491

A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme

NCT05600491

Phase 3 Unknown 78 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This study was to explore the effectiveness and safety of early TMZ chemotherapy between surgery and chemoradiotherapy plus the standard concomitant radiochemotherapy regimen.

Timeline

Start
2015-11-08
Primary completion
2022-12-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Temozolomide Small molecule 200 mg/m2 Oral